Physician profile
Alan M Antfleck
NPI 1154365559
$20,451.36
in general payments reported to CMS, 2019-2025
62 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,831 · 2020: $2,530 · 2021: $3,703 · 2022: $2,624 · 2023: $2,612 · 2024: $2,486 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,763.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,145.36 | 2019-2025 | Farxiga, Breztri, Wainua |
| Novo Nordisk INC | $2,307.47 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,796.84 | 2019-2024 | Repatha, Otezla, Prolia |
| Sanofi-Aventis U.S. LLC | $1,114.98 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,077.28 | 2019-2024 | |
| Abbvie INC. | $1,026.27 | 2019-2024 | Lo Loestrin Fe, Orilissa |
| Phathom Pharmaceuticals, INC. | $836.49 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $751.96 | 2019-2022 | |
| Lilly USA, LLC | $704.13 | 2019-2024 | Jardiance, Emgality, Zepbound |
| Pfizer INC. | $608.47 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $554.82 | 2019-2025 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $505.39 | 2021 | |
| Esperion Therapeutics, INC. | $406.99 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $394.38 | 2023-2025 | Nuzyra |
| Allergan, INC. | $391.04 | 2019-2020 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Antfleck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.